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ABSTRACT 
This study compared Major Adverse Cardiac Event in patient with Acute Coronary Syndromes undergoing PCI with Drug Eluting Stents Vs Bare 
Metal Stents. A retrospective, observational study was carried out in an inpatient setting of the private tertiary care hospital. Patients with >18 years, 
diagnosed for Acute Coronary Syndromes (ACS), required intervention in coronary artery with implantation of Drug Eluting Stents (DES) or Bare Metal 
Stents (BMS) were recruited in the study. The data had been collected from file or database of the hospital. All subjects were followed for major adverse 
cardiac event. A total of 202 patients who underwent Percutaneous Coronary Intervention (PCI) were enrolled into DES group (N=101) and BMS group 
(N=101).  All patients were followed up at 1 month, 3 months, 6 months & 12 months for Major Adverse Cardiac Events (MACE). Clinical outcomes during 12 
months were compared between DES group & BMS group. There was no significant difference in baseline parameters including demographic, risk factors of 
ACS, diagnosis, angiographic parameters between both groups. Overall MACE rates were reported non-significantly high in BMS group patients (14.85%) 
compare to DES group patients (8.91%) (P=0.458). However, DES group had lower rates of death (0.99% vs 1.98%, P=0.57), rate of MI (3.96% vs 4.95% 
P=0.73), rate of revascularization (1.98% vs 3.96% p=0.42) & rate of sub acute thrombosis (1.98% vs 3.96% P=0.42) and higher rate of bleeding (1.98% vs 
0.99% p=0.57) compare to cohort-II. The use of DES in the setting of Acute Coronary Syndrome is associated with lower Major Adverse Cardiac Event 
(MACE) rate compared to BMS without compromising the overall safety over the course of one-year follow-up. The long-term safety of drug-eluting stents 
needs to be ascertained in large, randomized trials. 
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INTRODUCTION 
Coronary artery disease (CAD) is the leading cause of 
mortality and morbidity in the world and acute coronary syndromes 
(ACS), which encompass unstable angina (UA), non-ST-segment 
elevation myocardial infarction (NSTEMI) and ST-segment elevation 
myocardial infarction (STEMI), are the commonest causes of mortality in 
patients with CAD. India has the highest burden of acute coronary 
syndromes in the world, yet little is known about the treatments and 
outcomes of these diseases. There will be required to document the 
characteristics, treatments, and outcomes of patients with acute 
coronary syndromes who were admitted to hospitals in India [2]. 
Prospective, randomized clinical trials have shown that in-
stent restenosis is reduced by the use of drug-eluting stents, as 
compared with bare-metal stents. However, the use of drug-eluting 
stents has rapidly been expanded to all types of patients, including those 
with more complicated coronary lesions and in acute settings. Recently 
metaanalyses of randomized trials [3-4] and registries [5] have raised 
concern about incomplete neointimal coverage with a subsequent 
increase in late stent thromboses in patients with drug-eluting stents [6-7]. 
One randomized trial indicated that the implantation of drug-eluting 
stents was associated with an early reduction in death and myocardial 
infarction - an improvement that was lost during the subsequent 6 to 18 
months by a late increase in the same events [8]. We determined that the 
evaluation of large clinical registries might provide useful information 
concerning the long-term efficacy and safety of drug-eluting stents. 
Therefore, we evaluated the long-term outcome in all patients who 
underwent stent implantation. 
MATERIAL AND METHODS 
A retrospective, open label, observational study carried out in 
an inpatient setting of the private tertiary care hospital. The patients 
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recruited in the study as per the criteria given below. 
Inclusion criteria: 
1. Patients were >18 years old.  
2. Patients were diagnosed for Acute Coronary Syndromes (ACS). 
3. Patients were required intervention with implantation of Drug 
Eluting Stents (DES) or Bare Metal Stents (BMS).  
Exclusion criteria: 
1. Planned elective surgery necessitating discontinuation of 
clopidogrel within the regular planned period of clopidogrel 
administration 
2. Previous implantation of a Drug Eluting Stent (DES) or Bare 
Metal Stent (BMS).  
3. Patients in whom anti-platelet and/or anticoagulation 
therapy was contraindicated. 
4. Patients were participated in another randomized trial that 
clinically interferes with the present trial, or requires 
coronary angiography or other coronary artery imaging 
procedures.  
5. Incomplete information regarding patient 
The data had been collected from file or database of the 
hospital. All subjects were followed for major adverse cardiac event 
(MACE) including death, Myocardial infarction, Urgent revascularization, 
sub acute thrombosis & bleeding at 1 month, 3 months, 6 months & 12 
months after PCI. All collected data was analyzed in its group for clinical 
outcomes. All variables were analyzed using percentage, mean & 
standard deviation. Statistical difference between both cohorts was 
calculated by applying independent t-test & odds ratio. 
RESULT AND DISCUSSION 
There were 202 patients who underwent PCI between 
December 2008 and July 2009 was enrolled in retrospective, 
observational study. All these subjects were divided in two Cohorts. 
Cohort-1: Patients implanted Drug Eluting Stent (DES) (N=101) 
Cohort-2: Patients implanted Bare Metal stent (BMS) (N=101) 
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Out of the 202 patients, 87.13% (N=88) and 89.11% (N=90) 
were male patients in Cohort-1 & Cohort-2 respectively. The average age 
of the patients were 56.34 & 55.46 in Cohort-1 & Cohort-2 respectively 
(Table 1). Risk of acute coronary syndrome was increase with increasing 
age (Fig. 1). Average BMI in cohort 1 & cohort 2 were 25.25 Kg/m2 & 
28.87 Kg/m2 respectively. There was no significant difference in baseline 
demographic parameters between both groups (Table 1). 
There were no significant difference in hypertension (46.53% 
Vs 33.66% P=0.74), diabetes Mellitus-II (30.69% Vs 21.78% P=0.15), 
family history of CAD (22.77% Vs 24.75% P=0.06), prior history of CAD 
(15.84% Vs 11.88% P=0.42), smoker (14.85% Vs 22.77% P=0.15), 
tobacco chewer (15.84% Vs 8.91% P=0.15), hyperlipidemia (1.98% Vs 
1.98% P=1.00) in cohort-I & cohort-II respectively (Fig. 2).  
There were high number of subjects were reported as STEMI 
in both groups. STEMI was reported 35.64% (36) Vs 34.66% (35), 
p=0.88 in Cohort-1 & Cohort-2 respectively. NSTEMI was reported 
27.73% (28) Vs 31.68% (32), p=0.54 in Cohort-1 & Cohort-2 
respectively. Unstable angina was reported 29.7% (30) Vs 30.69% (31), 
p=0.88 in Cohort-1 & Cohort-2 respectively. Stable angina was reported 
6.93% (7) Vs 2.97% (3), p=0.21 in Cohort-1 & Cohort-2 respectively (Fig. 
3).  
During coronary angiography (CAG), It was found that the 
main culprit vessel in coronary artery disease was LAD (66.34% & 
54.45% in Cohort-1 & Cohort-2 respectively) followed by RCA (21.78% 
& 23.76% in Cohort-1 & Cohort-2 respectively). There were high 
numbers of subjects having coronary stenosis >90% in both cohorts 
(49.5% & 52.47% in Cohort-1 & Cohort-2 respectively). Detail coronary 
angiographic findings were shown in Table 2. 
Overall MACE rates were reported non-significantly high in 
Cohort-I (8.91%) compare to Cohort-II (14.85%) (P = 0.458). However, 
Cohort-I had lower rates of death (0.99% vs 1.98%, P=0.57), rate of MI 
(3.96% vs 4.95% P=0.73), rate of revascularization (1.98% vs 3.96% 
p=0.42) & rate of sub acute thrombosis (1.98% vs 3.96% P=0.42) 
compare to cohort II (Table 3). 
Over all MACE rate reported for both of the groups was 0.99% Vs 0.99% 
(P=1) at one month, 0.99% Vs 2.97% (P=0.34) at three months, 2.97% Vs 
3.96% (P=0.7) at six months and 3.96% Vs 6.93% (P=0.36) at twelve 
months in Cohort-1 & Cohort-2 respectively (Fig. 4).  
Safety and efficacy study result demonstrated that over all MACE 
and mortality rate appears lower in DES group compare to BMS group. 
However, it was not significant statistically. Further long term study is 
required to get more viable results with larger population.  
Table No. 1: Demographic parameters 
Parameters Cohort-I Cohort-II P-value 
Age 56.34 ± 10.93 55.46 ± 12.47 0.59 
Gender-Male 87.13% (88) 89.11% (90) 0.66 
Weight 68.02 ± 11.33 69.8 ± 0.29 0.29 
Height 164.2 ± 9.55 164 ± 7.08 0.88 
BMI 25.25 ± 3.81 28.87 ± 3.74 0.24 
BSA 1.74 ± 0.17 1.76 ±0.17 0.48 
 
Table No. 2: Angiographic findings 
Parameters Cohort-I Cohort-II P Value 
Type of Vessel 
LAD 66.34% (67) 54.45% (55) 0.09 
RCA 21.78% (22) 23.76% (24) 0.74 
LAD & RCA 4.95% (5) 3.96% (4) 0.73 
LCX 3.96% (4) 10.89% (11) 0.07 
RAMUS 1.98% (2) 0% (0) 0.29 
SVG Graft 0.99% (1) 0% (0) 0.5 
OM-2 0% (0) 3.96% (4) 0.14 
LCX &LAD 0% (0) 0.99% (1) 0.5 
LMCA 0% (0) 0.99% (1) 0.5 
RCA & LCX 0% (0) 0.99% (1) 0.5 
Lesion Class 
A 13.86% (14) 14.85% (15) 0.84 
B1 20.79% (21) 22.77% (23) 0.73 
B2 25.74% (26) 25.74% (26) 1 
C 39.6% (40) 36.63% (37) 0.66 
% stenosis 
>90% 49.5% (50) 52.47% (53) 0.67 
80-90% 48.51% (49) 44.55% (45) 0.57 
<80% 1.98% (2) 2.97% (3) 0.65 
Calcification 
None/Mild 72.27% (73) 70.29% (71) 0.76 
Moderate 19.8% (20) 19.8% (20) 1 
Severe 7.92% (8) 9.9% (10) 0.62 
Tortuosity 
<45 90.09% (91) 82.17% (83) 0.11 
45-90 9.9% (10) 17.82% (18) 0.11 
Thrombus 45.54% (46) 36.63% (37) 0.2 
Pre TIMI Flow 
0 41.58% (42) 52.47% (53) 0.12 
1 34.65% (35) 23.76% (24) 0.09 
2 18.81% (19) 14.85% (15) 0.45 
3 4.95% (5) 8.91% (9) 0.27 
 
Table No. 3: Major Adverse Cardiac Event 
Parameters Cohort-I Cohort-II P Value OR CI (95%) 
Death 0.99% (1) 1.98% (2) 0.57 0.5 0.04 to 5.54 
Myocardial infarction 3.96% (4) 4.95% (5) 0.73 0.79 0.20 to 3.03 
Revascularisation 1.98% (2) 3.96% (4) 0.42 0.49 0.08 to 2.73 
sub acute thrombosis 1.98% (2) 3.96% (4) 0.42 0.49 0.08 to 2.73 
Over all MACE 8.91% (9) 14.85% (15) 0.2 0.56 0.23 to 1.35 
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Fig. 1: Age wise distribution of patients 
 
Fig. 2: Risk factors of Acute Coronary Syndromes 
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Fig. 3: Diagnosis of Patients 
CONCLUSION 
The use of DES in the setting of Acute Coronary Syndrome is 
associated with lower Major Adverse Cardiac Event (MACE) rate 
compared to BMS without compromising the overall safety over the 
course of one-year follow-up. The long-term safety of drug-eluting stents 
needs to be ascertained in large, randomized trials. 
ACKNOWLEDGMENTS: 
The authors thanks to Kakadiya Hospital, Ahmedbad for her 
help in performing the study and for assistance in the collection of data. 
This study was not funded by any one. No other potential conflicts of 
interest relevant to this article were reported. 
REFERENCES: 
1. KJ Raihanathul Misiriya, N Sudhayakumar, S Abdul Khadar et 
al. The Clinical Spectrum of Acute Coronary Syndromes: 
Experience from a Major Center in Kerala. J. Assoc. Physicians 
India, 2009: 57; 377-83. 
2. Andrew MD, Chatterjee K. Angioplasty versus Bypass Surgery 
for Coronary Artery Disease. Circulation, 2002; 106: 187-90.  
3. Xavier D, Pais P, Xie C, et al. Treatment and outcomes of acute 
coronary syndromes in India (CREATE). The Lancet., 1962; 
371: 1435-42. 
4. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt 
DL. Late thrombosis of drug-eluting stents: a meta-analysis of 
randomized clinical trials. Am. J. Med. 2006: 119; 1056-61. 
5. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized 
controlled trials comparing drug-eluting vs. bare metal stents 
in coronary artery disease: a metaanalysis. Eur. Heart. J., 
2006: 27; 2784-814. 
6. Daemen J. Late coronary stent thrombosis of DES in routine 
clinical practice: data from large two-institutional cohort 
study, Lancet., 2007; 369: 667-78.  
7. Aoki J, Colombo A, Dudek D, et al.Persistent remodeling and 
neointimal suppression 2 years after polymer-based, 
paclitaxel- eluting stent implantation: insights from serial 
Chetan R. Patel et al., Jour. of Phar. Res. 2012, 1(1), 12-15 
                  Journal of Pharma Research 2012, 1(1)   12-15 
intravascular ultrasound analysis in the TAXUS II study. 
Circulation, 2005; 112: 3876-83. 
8. Fujii K, Carlier SG, Mintz GS, et al. Stent under expansion and 
residual reference segment stenos is are related to stent 
thrombosis after sirolimus-eluting stent implantation: an 
intravascular ultrasound study. J. Am. Coll. Cardiol., 2005: 45; 
995-98. 
9. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late 
clinical events after clopidogrel discontinuation may limit the 
benefit of drug-eluting stents: an observational study of drug-
eluting versus baremetal stents. J. Am. Coll. Cardiol., 2006: 
48; 2584-91. 
 
 
 
 
 
 
 
Source of support: Nil, Conflict of interest: None Declared 
